QIAGEN N.V. (QGEN) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:QGEN - NL0015002CX3 - Common Stock
QGEN Key Statistics, Chart & Performance
The current stock price of QGEN is 45.04 USD. In the past month the price increased by 1.99%. In the past year, price increased by 0.76%.
QGEN Latest News, Press Relases and Analysis
QGEN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.53 | 214.87B | ||
| DHR | DANAHER CORP | 29.27 | 159.40B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 174.63 | 53.07B | ||
| A | AGILENT TECHNOLOGIES INC | 24.87 | 39.35B | ||
| IQV | IQVIA HOLDINGS INC | 19.18 | 37.99B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.16 | 28.34B | ||
| WAT | WATERS CORP | 29.79 | 22.52B | ||
| ILMN | ILLUMINA INC | 30.33 | 20.21B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 37.92 | 19.29B | ||
| MEDP | MEDPACE HOLDINGS INC | 39.35 | 15.85B | ||
| TEM | TEMPUS AI INC | N/A | 12.26B | ||
| RVTY | REVVITY INC | 20.64 | 11.21B |
Related stock screener links
About QGEN
Company Profile
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,700 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Company Info
QIAGEN N.V.
Hulsterweg 82
Venlo LIMBURG 5912 NL
CEO: Thierry Bernard
Employees: 5700
Phone: 31773556600
QIAGEN N.V. / QGEN FAQ
Can you describe the business of QIAGEN N.V.?
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,700 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
What is the stock price of QIAGEN N.V. today?
The current stock price of QGEN is 45.04 USD. The price increased by 0.07% in the last trading session.
Does QGEN stock pay dividends?
QIAGEN N.V. (QGEN) has a dividend yield of 0.55%. The yearly dividend amount is currently 0.
What is the ChartMill rating of QIAGEN N.V. stock?
QGEN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
How is the valuation of QIAGEN N.V. (QGEN) based on its PE ratio?
The PE ratio for QIAGEN N.V. (QGEN) is 19. This is based on the reported non-GAAP earnings per share of 2.37 and the current share price of 45.04 USD.
When does QIAGEN N.V. (QGEN) report earnings?
QIAGEN N.V. (QGEN) will report earnings on 2026-02-03, after the market close.
What is the outstanding short interest for QIAGEN N.V.?
The outstanding short interest for QIAGEN N.V. (QGEN) is 2.6% of its float.
QGEN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to QGEN. When comparing the yearly performance of all stocks, QGEN is a bad performer in the overall market: 62.28% of all stocks are doing better.
QGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to QGEN. Both the health and profitability get an excellent rating, making QGEN a very profitable company, without any liquidiy or solvency issues.
QGEN Financial Highlights
Over the last trailing twelve months QGEN reported a non-GAAP Earnings per Share(EPS) of 2.37. The EPS increased by 9.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.58% | ||
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| Debt/Equity | 0.45 |
QGEN Forecast & Estimates
24 analysts have analysed QGEN and the average price target is 51.67 USD. This implies a price increase of 14.71% is expected in the next year compared to the current price of 45.04.
For the next year, analysts expect an EPS growth of 9.25% and a revenue growth 5% for QGEN